GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Cyclically Adjusted Price-to-FCF

Nova Mentis Life Science (Nova Mentis Life Science) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nova Mentis Life Science Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Nova Mentis Life Science's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Cyclically Adjusted Price-to-FCF Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nova Mentis Life Science Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nova Mentis Life Science's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Nova Mentis Life Science's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Mentis Life Science's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nova Mentis Life Science's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nova Mentis Life Science's Cyclically Adjusted Price-to-FCF falls into.



Nova Mentis Life Science Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Nova Mentis Life Science's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Nova Mentis Life Science's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0/126.2576*126.2576
=0.000

Current CPI (Mar. 2024) = 126.2576.

Nova Mentis Life Science Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -0.003 96.945 -0.004
201403 0.000 98.604 0.000
201406 -0.019 99.473 -0.024
201409 -0.054 99.394 -0.069
201412 -0.011 98.367 -0.014
201503 -0.023 99.789 -0.029
201506 -0.003 100.500 -0.004
201509 -0.013 100.421 -0.016
201512 -0.020 99.947 -0.025
201603 -0.004 101.054 -0.005
201606 0.000 102.002 0.000
201609 -0.016 101.765 -0.020
201612 -0.018 101.449 -0.022
201703 -0.008 102.634 -0.010
201706 -0.014 103.029 -0.017
201709 -0.009 103.345 -0.011
201712 -0.020 103.345 -0.024
201803 -0.014 105.004 -0.017
201806 -0.003 105.557 -0.004
201809 -0.005 105.636 -0.006
201812 -0.014 105.399 -0.017
201903 -0.006 106.979 -0.007
201906 -0.005 107.690 -0.006
201909 -0.005 107.611 -0.006
201912 -0.004 107.769 -0.005
202003 -0.004 107.927 -0.005
202006 -0.002 108.401 -0.002
202009 -0.002 108.164 -0.002
202012 -0.003 108.559 -0.003
202103 -0.005 110.298 -0.006
202106 -0.003 111.720 -0.003
202109 -0.003 112.905 -0.003
202112 -0.004 113.774 -0.004
202203 -0.004 117.646 -0.004
202206 -0.003 120.806 -0.003
202209 -0.001 120.648 -0.001
202212 -0.001 120.964 -0.001
202303 -0.001 122.702 -0.001
202309 0.000 125.230 0.000
202403 0.000 126.258 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nova Mentis Life Science  (OTCPK:NMLSF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Nova Mentis Life Science Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus